The US Food and Drug Administration's No. 2, who came to the agency from a company pushing for increased use of real-world evidence, is not convinced the data is ready for full implementation in drug development.
Amy Abernethy, the agency's principal deputy commissioner, told an industry audience that momentum is building for increased use of RWE,...








